Small biotech startups are often focused entirely on the science. Legal considerations feel like a distraction when you are trying to achieve IND approval or reach a development milestone. But the decisions made about contracts, NDAs, and IP protection in the early stages of a biotech company have consequences that can take years to surface and be enormously expensive to fix. At Lopes Law LLC, we work with small biotech and biopharma clients who need practical, cost-conscious legal counsel from an attorney who understands both the legal landscape and the drug development process.

This guide covers the legal documents every biotech startup needs from day one, the IP protection issues that are most commonly missed, how to negotiate NDAs with large pharma partners, and what legal considerations become critical as the company grows from startup to clinical-stage.

What Legal Documents Does Every Biotech Startup Need?

Most biotech founders focus on scientific progress and funding before thinking about legal documents. This is understandable, but it creates significant risks. The following documents are non-negotiable for any biotech startup, and most should be in place before the company engages any third party in partnership or development discussions.

Confidentiality Agreements

Every person who learns about your compound, platform, or development program should sign a confidentiality agreement before the disclosure. This includes: co-founders during early discussions (before entity formation), scientific advisors, potential investors receiving a pitch deck or data room, employees during the hiring process, consultants engaged for technical work, and potential development partners or licensees. The NDA or CDA executed before any scientific disclosure is the first line of protection for your intellectual property.

Founder IP Assignment Agreements

This is the single most commonly missing document at early-stage biotech companies. Before any outside investment is accepted, all founders must formally assign their contributions to the company’s IP to the company entity. If a founder developed the lead compound in a university lab before the company was formed, or conducted foundational research as part of their doctoral work, the assignment must address those pre-existing contributions specifically.

Investors will conduct IP due diligence before any financing round. If there is any ambiguity about whether the company owns all of the IP that its technology is based on, the financing will stall or fail. At Lopes Law LLC, we advise founders to complete IP assignment agreements as the first legal step after entity formation, not as an afterthought before a funding close.

Contractor and Consultant Agreements

Any person who performs work for the biotech company on a contractor or consultant basis must sign an agreement that includes: (1) a work-for-hire clause establishing that all work product is owned by the company; (2) an IP assignment clause assigning all inventions made in connection with the engagement to the company; and (3) confidentiality obligations. Without these provisions, a consultant who develops a key assay or identifies a lead compound variant has a colorable claim to ownership of that work product under general intellectual property principles.

Material Transfer Agreements (MTAs)

When a biotech receives biological materials from an academic institution, a national laboratory, or another company, an MTA governs the transfer. The MTA specifies the permitted use of the materials and the IP rights in results generated using those materials. A biotech that receives materials under an MTA and then generates a patentable invention using those materials may have an obligation to share rights to that invention with the material provider. Understanding the MTA terms before accepting materials is essential.

Employment Agreements with IP Assignment

Every employee, including scientific and technical staff, must sign an employment agreement that includes IP assignment provisions. The IP assignment must cover all inventions made in connection with the employee’s work at the company, including inventions made outside of working hours if they relate to the company’s technology. The provisions must comply with applicable state law: California, Delaware, Illinois, Minnesota, North Carolina, and Washington have specific statutory limitations on employee IP assignment provisions.

What IP Protection Issues Are Critical for Biotech Startups?

Biotech startups face IP protection challenges that differ materially from those facing software or consumer product startups. The pharmaceutical regulatory timeline means that a drug compound may not reach commercial sale for 10 to 15 years after initial discovery. IP protection strategies must be durable over that timeline.

Founder IP Assignment: The Critical First Step

As noted above, founder IP assignment is the most commonly missed step. The specific issues that arise most often: (1) a founder who is also a university faculty member; the university may claim rights to inventions developed using university resources; (2) a founder who has prior employer agreements that could claim rights to inventions in a related field; and (3) a founding team that includes an inventor and a business co-founder where the inventor’s contributions are not clearly defined.

Joint Development and Co-Ownership

When two organizations collaborate on research (a biotech and an academic lab, a biotech and a contract research organization), IP ownership of jointly developed results must be addressed upfront in the agreement. Under US patent law, each co-owner of a jointly owned patent can license or exploit the patent without the other co-owner’s consent. This default rule means that a jointly owned patent with an academic collaborator could be licensed by the academic institution to a competitor without the biotech’s approval. The joint development agreement must modify this default rule explicitly.

Patent Strategy: Provisional, Utility, and PCT

A provisional patent application establishes a priority date at a lower cost than a full utility application and gives the applicant 12 months to file a full utility application. For biotech startups, provisional patents are an important tool for establishing priority on key compound claims before entering discussions with large pharma partners.

The NDA or CDA buys you some time before disclosing compound data, but it is not a substitute for a patent. An NDA prevents the receiving party from using your information without authorization; a patent prevents anyone from practicing the claimed compound or method, regardless of whether they received information from you. Both protections are necessary.

Trade Secrets: What to Patent vs. What to Keep Confidential

Not all valuable pharma IP should be patented. Manufacturing processes, in particular, are often better protected as trade secrets because: (1) a patent application requires public disclosure; (2) a manufacturing process can be kept confidential for decades, long after any patent would expire; and (3) trade secret protection has no fixed expiration. The decision between patent and trade secret protection requires a case-by-case analysis of the specific information, the competitive landscape, and the company’s development stage.

How Should Small Biotechs Negotiate NDAs with Large Pharma Partners?

The power imbalance in NDA negotiations between small biotech companies and large pharma partners is real. The large pharma will use its standard NDA template, which is drafted to protect its own interests. The small biotech may be receiving its first approach from a major pharmaceutical company and may feel pressure to sign quickly to maintain the relationship.

Know Your Non-Negotiables Before the NDA Arrives

Before the large pharma’s standard NDA arrives, the small biotech should prepare a list of provisions that are genuinely non-negotiable given the specific information to be disclosed. For a preclinical-stage company sharing compound synthesis data, the non-negotiables include: deletion of the residuals clause (or an explicit carve-out for compound structures and synthesis routes), a tight definition of permitted use tied to the specific transaction being evaluated, and a clear statement that no rights are granted to the disclosed information beyond the permitted use.

Understanding the Timeline Pressure

Large pharma companies frequently present NDAs with short signature deadlines: “we need this back in 3 business days.” This urgency is often real but also often negotiable. The 3-day deadline is designed to prevent the small biotech from having the NDA thoroughly reviewed before signing. A small biotech should push back on artificial urgency and take the time needed to have the agreement reviewed. A 5-day NDA review with proper legal counsel is far cheaper than a post-disclosure dispute about a residuals clause.

At Lopes Law LLC, we review pharma and biotech partnership NDAs for small biotech clients and identify the provisions that create the most risk given the client’s specific development stage and information to be shared. Our flat fee review process is designed to be fast and cost-effective without sacrificing the analysis that matters.

Client Scenario: The NDA That Almost Cost a Compound Series

A two-person biotech startup working on a novel kinase inhibitor series was approached by a Fortune 100 pharmaceutical company interested in evaluating a potential licensing arrangement for the lead compound. The large pharma company sent their standard mutual NDA for signature, flagging a 3-day deadline before the parties’ first technical call.

The founders, excited by the opportunity, were prepared to sign without review. Their scientific advisor recommended they consult At Lopes Law LLC before signing anything. We reviewed the NDA within 48 hours. The standard form included a residuals clause that would have permitted the large pharma’s scientists to use detailed knowledge of the compound synthesis route and SAR data without restriction after the discussions ended. The permitted use clause was also broader than necessary, allowing the large pharma to use the disclosed data to evaluate any potential transaction with the biotech, not just the specific licensing arrangement under discussion.

We provided a redline negotiating the deletion of the residuals clause and narrowing the permitted use to the specific licensing transaction. The large pharma accepted both changes without significant pushback, which itself suggested that the provisions were standard form rather than genuinely important to the large pharma’s interests. The NDA review took 2 days and cost a fraction of what the compound series was worth. At Lopes Law LLC, this is exactly the kind of high-stakes, time-sensitive engagement we handle for early-stage biotech clients.

What Legal Issues Become Critical as Biotech Grows from Startup to Clinical Stage?

As a biotech company progresses from concept to clinical stage, the legal issues evolve. The documents that were critical at formation are supplemented by a new layer of agreements and regulatory compliance obligations.

IND Application and Regulatory Compliance Agreements

Filing an IND (Investigational New Drug Application) with the FDA requires a series of agreements with the parties conducting and supporting the preclinical and clinical work: toxicology labs (GLP toxicology study agreements), formulation chemists (CDMO agreements), and CROs conducting the first-in-human study. Each of these agreements must address IP ownership, data rights, regulatory submission rights, and confidentiality. The IP ownership provisions in these agreements determine who owns the data package that will support future regulatory filings.

Investor and Board Agreements

Venture capital financing requires complex legal agreements: term sheets, certificate of incorporation amendments for preferred stock, investor rights agreements, voting agreements, and right of first refusal agreements. These agreements define the company’s capital structure and governance and have long-term implications for future financing rounds and eventual exit transactions.

Licensing and Partnership Agreements

A clinical-stage biotech pursuing a licensing or co-development deal with a large pharma company is entering one of the most complex transactions in the commercial life sciences sector. The licensing agreement terms: upfront payment, development milestones, royalty rates, sublicensing provisions, and diligence obligations will determine the company’s financial future. At this stage, experienced pharma licensing counsel is essential.

At Lopes Law LLC, we work with biotech companies at every stage, from pre-seed startups forming their first entity and executing founder IP assignments, through clinical-stage companies negotiating licensing agreements with Fortune 500 pharma partners. Our flat fee structure makes legal costs predictable for startups managing tight budgets. NDA reviews start at $1,500, and more complex engagement scopes are quoted after a free initial consultation.

For a detailed guide to pharma NDAs, see our post on Pharmaceutical NDAs: What Biotech and Pharma Companies Need to Know. For pharma confidentiality agreements beyond the NDA, see Confidentiality Agreements in Pharmaceutical Development. For cross-border agreement considerations, see our guide on Cross-Border NDA and CDA Agreements.

Reach out, we are friendly. Call now for a free consultation at (267) 777-9117 or schedule your free 20-minute consultation online.